Antidepressant prescriptions and associated factors in men with prostate cancer and their female partners
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Antidepressant prescriptions and associated factors in men with prostate cancer and their female partners. / Hartung, Tim J.; Moustsen, Ida Rask; Larsen, Signe Benzon; Wreford Andersen, Elisabeth A.; Suppli, Nis P.; Johansen, Christoffer; Tjønneland, Anne; Friberg, Anne S.; Kjær, Susanne K.; Brasso, Klaus; Kessing, Lars V.; Mehnert, Anja; Dalton, Susanne Oksbjerg.
In: Journal of Cancer Survivorship, Vol. 15, 2021, p. 536–545.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Antidepressant prescriptions and associated factors in men with prostate cancer and their female partners
AU - Hartung, Tim J.
AU - Moustsen, Ida Rask
AU - Larsen, Signe Benzon
AU - Wreford Andersen, Elisabeth A.
AU - Suppli, Nis P.
AU - Johansen, Christoffer
AU - Tjønneland, Anne
AU - Friberg, Anne S.
AU - Kjær, Susanne K.
AU - Brasso, Klaus
AU - Kessing, Lars V.
AU - Mehnert, Anja
AU - Dalton, Susanne Oksbjerg
PY - 2021
Y1 - 2021
N2 - Purpose: To estimate the risk of first-time antidepressant prescriptions as a proxy for depression or anxiety and associated risk factors in patients with prostate cancer and their female partners. Methods: We followed all men (n = 25,126) and their female cohabiting partners (n = 8785) without a history of cancer or antidepressants from the Danish Diet, Cancer and Health cohort from 1997 to 2014 or 2010, respectively. We estimated the cumulative incidence of first-time antidepressant prescriptions in men with prostate cancer compared with cancer-free men and their respective female partners, using the Danish National Prescription Registry. Sociodemographic, lifestyle-related, and clinical risk factors were assessed using Cox regression models. Results: A total of 1828 men were diagnosed with prostate cancer of whom 15% received antidepressants. The unadjusted hazard ratio of antidepressant prescription was 2.18 (95%CI, 1.92, 2.48) for men with prostate cancer and 1.27 (95%CI, 0.87, 1.85) for their partners, compared with cancer-free men and their partners, respectively. After adjusting for sociodemographic, lifestyle-related, and comorbidity factors, this risk was 2-fold to 4-fold increased among patients, but not significantly increased among partners. Significant risk factors among patients were curative and palliative treatment (vs. active surveillance and watchful waiting), nonlocalized disease, and short education. Conclusions: Men with prostate cancer have a higher risk of receiving antidepressant medication than cancer-free men. Clinical characteristics can help clinicians in identifying patients at a high risk of depression or anxiety. Implications for Cancer Survivors: Men with prostate cancer who experience symptoms of depression or anxiety should seek professional help early on. Patient education could aid in raising awareness and reducing the stigma associated with mental disorders.
AB - Purpose: To estimate the risk of first-time antidepressant prescriptions as a proxy for depression or anxiety and associated risk factors in patients with prostate cancer and their female partners. Methods: We followed all men (n = 25,126) and their female cohabiting partners (n = 8785) without a history of cancer or antidepressants from the Danish Diet, Cancer and Health cohort from 1997 to 2014 or 2010, respectively. We estimated the cumulative incidence of first-time antidepressant prescriptions in men with prostate cancer compared with cancer-free men and their respective female partners, using the Danish National Prescription Registry. Sociodemographic, lifestyle-related, and clinical risk factors were assessed using Cox regression models. Results: A total of 1828 men were diagnosed with prostate cancer of whom 15% received antidepressants. The unadjusted hazard ratio of antidepressant prescription was 2.18 (95%CI, 1.92, 2.48) for men with prostate cancer and 1.27 (95%CI, 0.87, 1.85) for their partners, compared with cancer-free men and their partners, respectively. After adjusting for sociodemographic, lifestyle-related, and comorbidity factors, this risk was 2-fold to 4-fold increased among patients, but not significantly increased among partners. Significant risk factors among patients were curative and palliative treatment (vs. active surveillance and watchful waiting), nonlocalized disease, and short education. Conclusions: Men with prostate cancer have a higher risk of receiving antidepressant medication than cancer-free men. Clinical characteristics can help clinicians in identifying patients at a high risk of depression or anxiety. Implications for Cancer Survivors: Men with prostate cancer who experience symptoms of depression or anxiety should seek professional help early on. Patient education could aid in raising awareness and reducing the stigma associated with mental disorders.
KW - Antidepressant agents
KW - Anxiety disorders
KW - Depression
KW - Diet
KW - Life style
KW - Prostatic neoplasms
U2 - 10.1007/s11764-020-00947-y
DO - 10.1007/s11764-020-00947-y
M3 - Journal article
C2 - 33051756
AN - SCOPUS:85092443414
VL - 15
SP - 536
EP - 545
JO - Journal of Cancer Survivorship
JF - Journal of Cancer Survivorship
SN - 1932-2259
ER -
ID: 250476812